T-cells are crucial to the body’s immune response to cancer, both endogenously and following therapeutic intervention. A T-cell marker panel that can identify subsets of tumor-associated T-cells allows scientists to identify and target subpopulations of T-cells playing unique roles in the immune response against a tumor. Bethyl's portfolio consists of polyclonal and monoclonal antibodies, including new recombinant rabbit monoclonal antibodies.
Bethyl has applied B-cell sorting and recombinant DNA technology to our unparalleled on-site manufacturing process to deliver high quality recombinant rabbit monoclonal antibodies (RmAbs). Designed with a 100% guarantee to work in validated applications to ensure that you spend less time re-doing experiments and more time researching.
Bromodomain protein 4 (BRD4) is a transcriptional regulator that plays a key role in cancer, autoimmunity, and inflammatory diseases. BRD4 was discovered as a protein bound to acetylated chromatin during cell cycle progression. In this way BRD4 maintains consistent gene expression during subsequent rounds of division, a phenomenon known as epigenetic memory or "bookmarking" for gene transcription.
Trial sizes are ideal for comparisons between suppliers or various application testings and cost effective at $99 US. Over 6,000 trial-sized antibodies are available to more than 3,300 protein targets, and new releases are continuing to be added every month.
Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.
The hypoxic response pathway is triggered by low levels of oxygen in the cellular environment. Hypoxia inducible transcription factor (HIF) is central to the hypoxic response. The overexpression of HIF1-alpha and HIF2-alpha is associated with poor survival rates for various cancers. Bethyl has expanded its capabilities and now offers rabbit recombinant monoclonal antibodies to HIF1-alpha and HIF2-alpha.